Literature DB >> 24366419

Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma.

Brian R Untch1, Frank L Palmer, Ian Ganly, Snehal G Patel, R Michael Tuttle, Jatin P Shah, Ashok A Shaha.   

Abstract

BACKGROUND: At our institution, thyroid lobectomy is employed as a definitive operation for unifocal intrathyroidal low risk cancers and thus completion thyroidectomy is rarely performed. The purpose of this study was to identify the indications for selective completion thyroidectomy and to report oncologic outcomes.
METHODS: A retrospective review was performed to identify patients who underwent planned completion thyroidectomy for well-differentiated thyroid carcinoma (WDTC) from 2001 to 2010 based on initial lobectomy pathology. Assessment for risk of recurrence was based on the American Thyroid Association Initial Risk Stratification.
RESULTS: During the 10-year study period, 79 patients underwent completion thyroidectomy for WDTC. Forty-four (56 %) patients were low risk and 35 (44 %) were intermediate risk. Completion thyroidectomy was recommended for 64 patients, whereas 15 patients were given an option of surveillance but ultimately decided to have surgery. Patients in the "recommended group" had more T3 tumors and fewer T1a tumors (p = 0.005 and 0.006, respectively). These patients also were more likely to be intermediate risk (p = 0.008) and to present with aggressive histology (p = 0.002). The rate of contralateral tumors (n = 27) was similar between both groups (35 and 33 %, respectively). Contralateral cancers were micropapillary in 24 of 27 (89 %) patients, 10 (40 %) of whom had multifocal disease. There were two pulmonary recurrences and no local-regional recurrences (median follow-up of 42.3 months).
CONCLUSIONS: Completion thyroidectomy is infrequent and performed for a select group of intermediate and low risk WDTCs at our institution with low recurrence rates. Incidental multifocal and unifocal contralateral cancers are common after completion thyroidectomy.

Entities:  

Mesh:

Year:  2013        PMID: 24366419     DOI: 10.1245/s10434-013-3428-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

2.  Total tumor diameter: the neglected value in papillary thyroid microcarcinoma.

Authors:  J-W Feng; H Pan; L Wang; J Ye; Y Jiang; Z Qu
Journal:  J Endocrinol Invest       Date:  2019-11-20       Impact factor: 4.256

Review 3.  Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma.

Authors:  Marco Raffaelli; Serena Elisa Tempera; Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2020-01

4.  Clinicopathological features of recurrent papillary thyroid cancer.

Authors:  Jian Zhu; Xinli Wang; Xiaoxuan Zhang; Peifeng Li; Haifeng Hou
Journal:  Diagn Pathol       Date:  2015-07-14       Impact factor: 2.644

5.  Should the Prevalence of Incidental Thyroid Cancer Determine the Extent of Surgery in Multinodular Goiter?

Authors:  Krzysztof Kaliszewski; Marta Strutyńska-Karpińska; Agnieszka Zubkiewicz-Kucharska; Beata Wojtczak; Paweł Domosławski; Waldemar Balcerzak; Tadeusz Łukieńczuk; Zdzisław Forkasiewicz
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

6.  2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma.

Authors:  Ming Gao; Minghua Ge; Qinghai Ji; Ruochuan Cheng; Hankui Lu; Haixia Guan; Li Gao; Zhuming Guo; Tao Huang; Xiaoming Huang; Xiaoming Li; Yansong Lin; Qinjiang Liu; Xin Ni; Yi Pan; Jianwu Qin; Zhongyan Shan; Hui Sun; Xudong Wang; Zhengang Xu; Yang Yu; Daiwei Zhao; Naisong Zhang; Sheng Zhang; Ying Zheng; Jingqiang Zhu; Dapeng Li; Xiangqian Zheng
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

7.  Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastasis.

Authors:  Jen-Der Lin; Shu-Fu Lin; Szu-Tah Chen; Chuen Hsueh; Chia-Lin Li; Tzu-Chieh Chao
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

8.  The Ongoing Debate Regarding Completion Thyroidectomy Versus Primary Thyroid Surgery for Low and Intermediate Differentiated Thyroid Carcinoma: A Meta-Analysis.

Authors:  Hyder Mirghani; Ibrahim A Altedlawi Albalawi
Journal:  Cureus       Date:  2020-12-11

9.  Surgical approaches for papillary microcarcinomas: Turkey's perspective.

Authors:  Özer Makay; Murat Özdemir; Yasemin Giles Şenyürek; Fatih Tunca; Mete Düren; Mehmet Uludağ; Mehmet Hacıyanlı; Gökhan Içöz; Adnan Işgör; Serdar Özbaş; Zehra Özcan; Serdar Tezelman
Journal:  Turk J Surg       Date:  2018-07-01

10.  Longitudinal Genomic Evolution of Conventional Papillary Thyroid Cancer With Brain Metastasis.

Authors:  Han Luo; Xue Liao; Yun Qin; Qianqian Hou; Zhinan Xue; Yang Liu; Feiyang Shen; Yuelan Wang; Yong Jiang; Linlin Song; Haining Chen; Lingyun Zhang; Tao Wei; Lunzhi Dai; Li Yang; Wei Zhang; Zhihui Li; Heng Xu; Jingqiang Zhu; Yang Shu
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.